Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Unresectable Pancreatic Cancer: early-phase trial registry

1 of 5 indexed Unresectable Pancreatic Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Unresectable Pancreatic Cancer: 5 US clinical trials tracked, 1 recruiting.

Unresectable Pancreatic Cancer is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 3 of these trials.

Enrollment posture brief

Registry condition unresectable-pancreatic-cancer

OPEN 1 | RECR 20% | LATE 0 | EARLY 3 | RANK #3391 | SPON 3

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Unresectable Pancreatic (th…20%
Open-enrollment share among volume-matched conditions near Unresectable Pancreatic Cancer

Unresectable Pancreatic Cancer lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Unresectable Pancreatic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Unresectable Pancreatic Cancer is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Unresectable Pancreatic Cancer research.

    Dana-Farber Cancer Institute accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.

  3. Most Unresectable Pancreatic Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 24 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.

  4. Unresectable Pancreatic Cancer research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2

Named interventions

Most-linked intervention names on Unresectable Pancreatic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Chemotherapy education intervention (CEI) Behavioral
1 trials
Usual chemotherapy education (CE) Behavioral
1 trials
Usual, standard-of-care informed consent for chemotherapy Other
1 trials
Investigational informed consent for chemotherapy Other
1 trials
Concurrent chemotherapy (Gemcitabine, Capecitabine) Drug
1 trials
Paclitaxel Protein Bound (Abraxane) Drug
1 trials
Radiotherapy Radiation
1 trials
AGuIX Drug
1 trials

US sites by state

Facility locations filed on Unresectable Pancreatic Cancer trials. A trial with sites in several states counts in each.

Massachusetts 3 trials
Wisconsin 1 trials
Virginia 1 trials
Texas 1 trials
New Mexico 1 trials
North Carolina 1 trials
Florida 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Unresectable Pancreatic Cancer page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Unresectable Pancreatic Cancer condition card totals 5 registered trials; most-linked intervention Chemotherapy education intervention (CEI); top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.